Questions: Beta-Lactam Antibiotics and Penicillin-Binding Protein Inhibition

Question 1

A patient with a bacterial infection has bacteria growing in a biofilm where many cells are metabolically dormant and not actively dividing. Why might penicillin treatment be less effective against these bacteria?

• A. Penicillin cannot diffuse through the biofilm matrix and never reaches the bacterial cells
• B. Dormant bacteria produce β-lactamase at much higher rates than actively growing cells
• C. Dormant bacteria are not synthesizing new peptidoglycan, so transpeptidation is not occurring and PBPs are not active drug targets
• D. The dormant bacteria express structurally different PBPs that the β-lactam ring cannot recognize

Answer: (C)

Beta-lactams target actively occurring transpeptidation — the cross-linking step of new peptidoglycan synthesis. Dormant, non-dividing bacteria are not building new cell wall material, so their PBPs are not engaged in catalysis. Since the drug works by trapping the enzyme in a covalent dead-end intermediate during its normal catalytic cycle, cells that aren't undergoing that cycle are far less vulnerable. This is why β-lactam antibiotics are most effective against rapidly growing bacteria and why persistent/biofilm infections are clinically challenging.

Question 2

What is the mechanism by which β-lactam antibiotics irreversibly inactivate penicillin-binding proteins?

• A. They bind to the ribosome, blocking synthesis of new PBP protein and depleting the cell's supply
• B. They form a stable covalent acyl-enzyme intermediate that the PBP cannot resolve — mimicking the normal D-Ala-D-Ala substrate but trapping the enzyme
• C. They chelate divalent metal ions in the PBP active site, disrupting its catalytic chemistry
• D. They competitively inhibit D-Ala-D-Ala binding reversibly, requiring continuous drug presence

Answer: (B)

This is molecular mimicry leading to covalent suicide inhibition. The β-lactam ring resembles the D-Ala–D-Ala terminal dipeptide of peptidoglycan precursors well enough that the PBP's active site attacks it and forms a covalent acyl-enzyme intermediate — exactly what it would do with the normal substrate. But the β-lactam-derived intermediate is hydrolytically stable and cannot be resolved. The enzyme is permanently inactivated, locked in a dead-end complex. This is why β-lactams are bactericidal rather than bacteriostatic — the inactivation is not reversed when drug is removed.

Question 3

Co-administering penicillin with clavulanic acid (a β-lactamase inhibitor) protects the antibiotic from enzymatic destruction, even though clavulanic acid does not directly kill bacteria.

• T. True
• F. False

Answer: True

This is the rationale behind combination drugs like Augmentin (amoxicillin + clavulanic acid). Clavulanic acid occupies the β-lactamase active site — it acts as a sacrificial β-lactam that the enzyme destroys before it can destroy the therapeutic antibiotic. By occupying β-lactamase, clavulanic acid shields the penicillin so it can reach and inhibit its true target (PBPs). Clavulanic acid itself has minimal antibacterial activity; its role is protective, not direct.

Question 4

Beta-lactam antibiotics are bacteriostatic — they inhibit bacterial growth but do not directly kill cells.

• T. True
• F. False

Answer: False

β-lactams are bactericidal, meaning they kill cells rather than merely inhibiting growth. With transpeptidases permanently inactivated, bacteria continue inserting new, uncrosslinked glycan strands into the wall while autolysins (which normally remodel the wall) continue breaking existing cross-links. The result is a progressively weakened, unrepaired cell wall that cannot withstand internal osmotic pressure. The cell swells and lyses — it physically bursts. This bactericidal mechanism distinguishes β-lactams from bacteriostatic drugs like tetracyclines or chloramphenicol, which inhibit growth without directly lysing cells.

Question 5

Explain why β-lactam antibiotics are most effective against actively dividing bacteria rather than dormant ones.

Model answer: Beta-lactams work by irreversibly inactivating transpeptidases (PBPs) during active peptidoglycan cross-linking. The drug mimics the D-Ala-D-Ala substrate, traps the enzyme in a covalent intermediate, and permanently disables it. This mechanism requires the enzyme to be actively engaged in catalysis — if bacteria are not synthesizing new cell wall material (as in dormant or slow-growing cells), their PBPs are not actively catalyzing transpeptidation and the drug has little opportunity to form the inactivating intermediate. Additionally, the bactericidal lysis mechanism requires autolysins to continue degrading old cross-links while new uncrosslinked strands accumulate — a process that only happens during active growth.

This growth-dependence has important clinical implications. Persistent bacterial cells (persisters) within biofilms or inside host cells are often non-growing and therefore tolerant to β-lactam treatment even without genetic resistance mutations. When antibiotics are discontinued, persisters can resume growth and repopulate the infection. This is distinct from resistance (where genetic changes protect the cell) — persisters are phenotypically tolerant, not genetically resistant.